Aldose reductase inhibitor
Their target, aldose reductase, is an enzyme that is normally present in many other parts of the body, and catalyzes one of the steps in the sorbitol(polyol) pathway that is responsible for fructose formation from glucose. Aldose reductase activity increases as the glucose concentration rises in diabetes in those tissues that are not insulin sensitive, which include the lenses, peripheral nerves and glomerulus. Sorbitol does not diffuse through cell membranes easily and therefore accumulates, causing osmotic damage which leads to retinopathy and neuropathy.
Examples of aldose reductase inhibitors include:
Diabetic cataract formation follows an increase in sugars in the lens. The excess sugar within the lens is reduced by aldose reductase to its alcohol, but the lens capsule is relatively impermeable to sugar alcohols. Because of the excess sugar alcohol (polyol), the lens imbibes water, causing osmotic imbalance. Eventually, increased sodium and decreased potassium levels and decreased glutathione levels lead to cataract formation. Topical administration of aldose reductase inhibitors have been shown to prevent the cataract in rats.
Asthma and COPD
This class of drugs is also under investigation as a possible root pathology modulating treatment for asthma and COPD since it has been shown that they inhibit goblet cell metaplasia in the respiratory epithelium, thereby reducing the copious mucous secretion associated with these.
- Várkonyi T, Kempler P (2007). "Diabetic neuropathy: new strategies for treatment". Diabetes, Obesity and Metabolism 10 (2): 070626012134005. doi:10.1111/j.1463-1326.2007.00741.x. PMID 17593238.
- Saraswat, M.; Muthenna, P.; Suryanarayana, P.; Petrash, J. M.; Reddy, G. B. (2008). "Dietary sources of aldose reductase inhibitors: Prospects for alleviating diabetic complications". Asia Pacific journal of clinical nutrition 17 (4): 558–565. PMID 19114390.
- Newell, FW. Ophthalmology: Principles and Concepts, Fifth Edition. London: The CV Mosby Company, 1982, p. 332.
- University of Texas Medical Branch at Galveston (2011, January 27). Discovery could lead to new therapies for asthma, COPD. ScienceDaily. Retrieved January 27, 2011, from http://www.sciencedaily.com /releases/2011/01/110127101325.htm?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+sciencedaily+%28ScienceDaily%3A+Latest+Science+News%29&utm_content=Google+Reader
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|